Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
The BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across distinct examiners and art units, each totaling 4. This distribution indicates that each pending matter is being reviewed in a different administrative environment by a different official.
LEITH, NANCY J is identified as the busiest examiner, though she is responsible for only 1 pending office action. This reflects the uniform distribution of the workload, as each of the 4 distinct examiners is handling exactly one of the 4 pending office actions. There is no concentration of cases under any single examiner or within any single art unit involved.
For practitioners, this spread across the Biotechnology & Pharmaceuticals sector requires a versatile strategy. Since each pending office action is being evaluated by a different examiner, the institute must navigate four separate sets of examiner preferences and art unit norms simultaneously. This lack of overlap means that insights gained from one examiner may not directly apply to the other pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029400 | EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR | AEDER, SEAN E | 22d |
| 18028502 | ACTIVATED PLURIPOTENT STEM CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WILSON, MICHAEL C | 27d |
| 18564488 | ENGINEERED CAS12I NUCLEASE, EFFECTOR PROTEIN AND USE THEREOF | LEITH, NANCY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029400 | EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR | AEDER, SEAN E | 22d |
| 18028502 | ACTIVATED PLURIPOTENT STEM CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WILSON, MICHAEL C | 27d |
| 18564488 | ENGINEERED CAS12I NUCLEASE, EFFECTOR PROTEIN AND USE THEREOF | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1642 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564488 | ENGINEERED CAS12I NUCLEASE, EFFECTOR PROTEIN AND USE THEREOF | LEITH, NANCY J | 1683 | §102§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18029400 | EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR | AEDER, SEAN E | 1642 | §102§103 | Non-Final OA | 22d | Pending | May 04, 2023 |
| 18028502 | ACTIVATED PLURIPOTENT STEM CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WILSON, MICHAEL C | 1638 | §102§112Other | Non-Final OA | 27d | Pending | Mar 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial